Christopher Thomas Giordano - Jun 9, 2022 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
CEO, Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Stock symbol
TENX
Transactions as of
Jun 9, 2022
Transactions value $
$0
Form type
4
Date filed
6/10/2022, 09:15 PM
Previous filing
Jul 15, 2021
Next filing
May 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +200K $0.00 200K Jun 9, 2022 Common Stock 200K $0.62 Direct F1
holding TENX Stock Option (right to buy) 250K Jun 9, 2022 Common Stock 250K $1.97 Direct F2
holding TENX Stock Option (right to buy) 100K Jun 9, 2022 Common Stock 100K $1.97 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest and become exercisable as follows: options with respect to 50,000 underlying shares of Common Stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F2 The options vest and become exercisable as follows: options with respect to 62,500 underlying shares of Common Stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
F3 The options vest in two tranches upon achievement of certain performance metrics: 50% upon initiation of a Phase 3 trial for levosimendan by June 30, 2022; and 50% upon initiation of a Phase 3 trial for imatinib by June 30, 2022, subject to the Reporting Person's continued employment.